To describe the clinical and radiological characteristics and outcomes of patients with aquaporin-4-immunoglobulin G (AQP4-IgG) seropositive neuromyelitis optica spectrum disorder (NMOSD) coexisting with systemic lupus erythematosus (SLE) and primary Sjögren's syndrome (pSS) in a single center.
Methods
We included patients with diagnosis of NMOSD and a concomitant diagnosis of SLE or pSS. Demographic, clinical, serological and imaging characteristics were retrieved from clinical charts.
Results
Twelve patients were included, of whom 11 (91.7%) were women. Seven (58.3%) had SLE and five (41.7%) pSS. In five (41.7%) patients NMOSD followed SLE/pSS onset, four (33.3%) patients had a simultaneous presentation, and in three (25%) NMOSD preceded pSS onset. The mean age at first neurological event was 39 years. Eleven patients (91.7%) experienced acute transverse myelitis/longitudinally extensive transverse myelitis, five (41.7%) optic neuritis, three (25%) a cerebral syndrome and two (16.7%) each area postrema syndrome, acute brainstem syndrome and cerebellar syndrome. Eleven (91.7%) patients went into either total or partial NMOSD remission at median follow-up of 89.5 months.
Conclusion
AQP4-IgG seropositive NMOSD arose in the context of quiescent SLE and pSS with extraglandular features. As NMOSD coexisting with SLE/pSS is rare, collaborative multicenter studies are needed to clarify the natural history and outcomes of this overlap syndrome.
WingerchukDMBanwellBBennettJL, et al.International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology2015; 85: 177–189.
2.
LennonVAWingerchukDMKryzerTJ, et al.A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet2004; 364: 2106–2112.
3.
WingerchukDMLennonVALucchinettiCFPittockSJWeinshenkerBG. The spectrum of neuromyelitis optica. Lancet Neurol2007; 6: 805–815.
4.
TanEMCohenASFriesJF, et al.The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum1982; 25: 1271–1277. .
5.
VitaliCBombardieriSJonssonR, et al.Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis2002; 61: 554–558. .
6.
FlanaganEPWeinshenkerBGKreckeKN, et al.Short myelitis lesions in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorders. JAMA Neurol2015; 72: 81–87.
7.
BirnbaumJPetriMThompsonRIzbudakIKerrD. Distinct subtypes of myelitis in systemic lupus erythematosus. Arthritis Rheum2009; 60: 3378–3387.
8.
KremerLMealyMJacobA, et al.Brainstem manifestations in neuromyelitis optica: a multicenter study of 258 patients. Mult Scler2014; 20: 843–847.
9.
VernantJCCabrePSmadjaD, et al.Recurrent optic neuromyelitis with endocrinopathies: a new syndrome. Neurology1997; 48: 58–64.
10.
KimHJPaulFLana-PeixotoMA, et al.MRI characteristics of neuromyelitis optica spectrum disorder: an international update. Neurology2015; 84: 1165–1173.
11.
BombardierCGladmanDDUrowitzMBCaronDChangCH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum1992; 35: 630–640.
12.
SerorRRavaudPBowmanSJ, et al.EULAR Sjogren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren's syndrome. Ann Rheum Dis2010; 69: 1103–1109.
13.
GladmanDGinzlerEGoldsmithC, et al.The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum1996; 39: 363–369.
14.
VitaliCPalombiGBaldiniC, et al.Sjögren's syndrome disease damage index and disease activity index: scoring systems for the assessment of disease damage and disease activity in Sjögren's syndrome, derived from an analysis of a cohort of Italian patients. Arthritis Rheum2007; 56: 2223–2231. .
15.
KurtzkeJF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology1983; 33: 1444–1452.
16.
KirshblumSCWaringWBiering-SorensenF, et al.Reference for the 2011 revision of the International Standards for Neurological Classification of Spinal Cord Injury. J Spinal Cord Med2011; 34: 547–554.
17.
AprilRSVansonnenbergE. A case of neuromyelitis optica (Devic's syndrome) in systemic lupus erythematosus. Clinicopathologic report and review of the literature. Neurology1976; 26: 1066–1070.
18.
PittockSJLennonVAde SezeJ, et al.Neuromyelitis optica and non organ-specific autoimmunity. Arch Neurol2008; 65: 78–83.
19.
PereiraWLCJReicheEMVKallaurAP, et al.Frequency of autoimmune disorders and autoantibodies in patients with neuromyelitis optica. Acta Neuropsychiatr2017; 29: 170–178.
20.
LinYCWangAGYenMY. Systemic lupus erythematosus-associated optic neuritis: clinical experience and literature review. Acta Ophthalmol2009; 87: 204–210.
21.
Quintanilla-GonzálezLAtisha-FregosoYLlorenteLFragoso-LoyoH. Myelitis in systemic lupus erythematosus: clinical characteristics and effect in accrual damage. A single-center experience. Lupus2017; 26: 248–254.
22.
Carvajal AlegriaGGuellecDMarietteX, et al.Epidemiology of neurological manifestations in Sjögren's syndrome: data from the French ASSESS Cohort. RMD Open2016; 2: e000179.
23.
MaderSJeganathanVArinumaY, et al.Understanding the antibody repertoire in neuropsychiatric systemic lupus erythematosus and neuromyelitis optica spectrum disorder: do they share common targets?. Arthritis Rheumatol2018; 70: 277–286.
24.
PröbstelAKThaneiMErniB, et al.Association of antibodies against myelin and neuronal antigens with neuroinflammation in systemic lupus erythematosus. Rheumatology (Oxford). 2019; 58: 908–913.
25.
JariusSJacobiCde SezeJ, et al.Frequency and syndrome specificity of antibodies to aquaporin-4 in neurological patients with rheumatic disorders. Mult Scler2011; 17: 1067–1073.
26.
BirnbaumJAtriNMBaerAN, et al.Relationship between neuromyelitis optica spectrum disorder and Sjögren's syndrome: central nervous system extraglandular disease or unrelated, co-occurring autoimmunity?. Arthritis Care Res (Hoboken)2017; 69: 1069–1075.
27.
ShahmohammadiSDoostiRShahmohammadiA, et al.Autoimmune diseases associated with neuromyelitis optica spectrum disorders: a literature review. Mult Scler Relat Disord2019; 27: 350–363. .
QiaoLWangQFeiY, et al.The clinical characteristics of primary Sjogren's syndrome with neuromyelitis optica spectrum disorder in China: a STROBE-compliant article. Medicine (Baltimore)2015; 94: e1145.
30.
Antonio-LunaEAcosta-CastilloGIOrtiz-MaldonadoJFEstrada-GalindoACoronaTFloresJ. [Comparison of neuromyelitis optica spectra according to AQP4 antibody serostatus in a Mexican referral centre]. Rev Neurol2017; 65: 311–321.
31.
Carnero ContenttiEDaccach MarquesVSoto de CastilloI, et al.Frequency of brain MRI abnormalities in neuromyelitis optica spectrum disorder at presentation: a cohort of Latin American patients. Mult Scler Relat Disord2018; 19: 73–78.
32.
Flores-SilvaFDLongoria-LozanoOAguirre-VillarrealD, et al.Natural history of longitudinally extensive transverse myelitis in 35 Hispanic patients with systemic lupus erythematosus: good short-term functional outcome and paradoxical increase in long-term mortality. Lupus2018; 27: 1279–1286.
33.
LavalleCPizarroSDrenkardCSánchez-GuerreroJAlarcón-SegoviaD. Transverse myelitis: a manifestation of systemic lupus erythematosus strongly associated with antiphospholipid antibodies. J Rheumatol1990; 17: 34–37.
34.
Aguirre-VillarrealDWhittallLPFragoso-LoyoHCantú-BritoCCrispínJCValdés-FerrerSI. Intrathecal formation of anticardiolipin antibodies in a patient with SLE-related relapsing longitudinal myelitis: a possible pathogenic connection. Lupus2018; 27: 2292–2295.
35.
XuYWangQRenHT, et al.Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and cyclophosphamide among patients with neuromyelitis optica spectrum disorder: a prospective cohort study. J Neurol Sci2016; 370: 224–228.
36.
GranadosJVargas-AlarcónGAndradeFMelín-AldanaHAlcocer-VarelaJAlarcón-SegoviaD. The role of HLA-DR alleles and complotypes through the ethnic barrier in systemic lupus erythematosus in Mexicans. Lupus1996; 5: 184–189.
37.
AlonsoVRde Jesus Flores RiveraJGarciYR, et al.Neuromyelitis optica (NMO IgG+) and genetic susceptibility, potential ethnic influences. Cent Nerv Syst Agents Med Chem2018; 18: 4–7. .
38.
GottenbergJEBussonMLoiseauP, et al.In primary Sjögren's syndrome, HLA class II is associated exclusively with autoantibody production and spreading of the autoimmune response. Arthritis Rheum2003; 48: 2240–2245.
39.
LianZLiuJShiZ, et al.Association of TNFSF4 polymorphisms with neuromyelitis optica spectrum disorders in a Chinese population. J Mol Neurosci2017; 63: 396–402.
40.
Beltrán RamírezOMendoza RincónJFBarbosa CobosREAlemán ÁvilaIRamírez BelloJ. STAT4 confers risk for rheumatoid arthritis and systemic lupus erythematosus in Mexican patients. Immunol Lett2016; 175: 40–43.
41.
ShiZZhangQChenH, et al.STAT4 polymorphisms are associated with neuromyelitis optica spectrum disorders. Neuromolecular Med2017; 19: 493–500.
